U.S. Physical Therapy's (USPH) Hold (C) Rating Reiterated at Weiss Ratings

Key Points

• U.S. Physical Therapy's stock has a "hold (c)" rating reaffirmed by Weiss Ratings, with a consensus rating of "Moderate Buy" and an average price target of $110.25.
• Recent trading data shows the stock reached $89.89 with a market cap of $1.37 billion, and has shown a year-over-year revenue increase of 18.0%.
• Insider trading activity includes sales by Director Nancy Ham and CEO Christopher J. Reading, indicating a decrease in their stock ownership of approximately 23.13% and 1.72% respectively.

U.S. Physical Therapy (NYSE:USPH - Get Free Report)'s stock had its "hold (c)" rating reiterated by equities researchers at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

A number of other analysts have also commented on USPH. Wall Street Zen lowered shares of U.S. Physical Therapy from a "buy" rating to a "hold" rating in a research report on Sunday, September 21st. Zacks Research raised shares of U.S. Physical Therapy to a "hold" rating in a research report on Friday, August 8th. JPMorgan Chase & Co. began coverage on shares of U.S. Physical Therapy in a report on Thursday, September 18th. They set an "overweight" rating and a $110.00 target price on the stock. Finally, Barrington Research boosted their target price on shares of U.S. Physical Therapy from $98.00 to $103.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $110.25.

U.S. Physical Therapy Stock Up 0.1%

USPH traded up $0.12 during trading on Wednesday, reaching $89.89. The company had a trading volume of 102,183 shares, compared to its average volume of 144,998. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.18 and a quick ratio of 1.18. U.S. Physical Therapy has a 12 month low of $62.77 and a 12 month high of $101.19. The business's fifty day moving average price is $82.65 and its 200 day moving average price is $77.05. The company has a market cap of $1.37 billion, a P/E ratio of 39.21, a PEG ratio of 4.49 and a beta of 1.48.

U.S. Physical Therapy (NYSE:USPH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.81 earnings per share for the quarter, beating analysts' consensus estimates of $0.71 by $0.10. The firm had revenue of $197.34 million for the quarter, compared to analyst estimates of $190.24 million. U.S. Physical Therapy had a net margin of 5.05% and a return on equity of 8.78%. The business's revenue was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.73 earnings per share. Equities analysts anticipate that U.S. Physical Therapy will post 2.67 EPS for the current year.

Insider Buying and Selling

In other news, Director Nancy Ham sold 600 shares of the business's stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $81.71, for a total value of $49,026.00. Following the completion of the sale, the director owned 1,994 shares of the company's stock, valued at approximately $162,929.74. The trade was a 23.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Christopher J. Reading sold 2,000 shares of the business's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $83.53, for a total transaction of $167,060.00. Following the completion of the sale, the chief executive officer directly owned 114,088 shares of the company's stock, valued at approximately $9,529,770.64. The trade was a 1.72% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,853 shares of company stock valued at $581,406 in the last 90 days. 2.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On U.S. Physical Therapy

Several institutional investors and hedge funds have recently bought and sold shares of USPH. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in U.S. Physical Therapy by 952.4% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 442 shares of the company's stock worth $32,000 after purchasing an additional 400 shares during the period. Parallel Advisors LLC lifted its position in U.S. Physical Therapy by 90.6% during the second quarter. Parallel Advisors LLC now owns 448 shares of the company's stock worth $35,000 after purchasing an additional 213 shares during the period. Cullen Frost Bankers Inc. lifted its position in U.S. Physical Therapy by 171.8% during the second quarter. Cullen Frost Bankers Inc. now owns 443 shares of the company's stock worth $35,000 after purchasing an additional 280 shares during the period. Assetmark Inc. lifted its holdings in shares of U.S. Physical Therapy by 35.7% in the second quarter. Assetmark Inc. now owns 570 shares of the company's stock worth $45,000 after acquiring an additional 150 shares during the last quarter. Finally, Huntington National Bank lifted its holdings in shares of U.S. Physical Therapy by 71.9% in the second quarter. Huntington National Bank now owns 667 shares of the company's stock worth $52,000 after acquiring an additional 279 shares during the last quarter.

About U.S. Physical Therapy

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.